Hand-foot syndrome histopathologically presenting eccrine squamous syringometaplasia due to pembrolizumab after lenvatinib treatment.

The authors declare no conflict of interest. The data that support the findings of this study are openly available. TABLE S1. CTCAE grades1 for hand-foot syndrome. TABLE S2. Major steroid for topical use. TABLE S3. Hand-foot syndrome from chemotherapy versus from multi-kinase inhibitors.2 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.